Syndax Announces Positive Data for Revumenib in Patients wit

Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , San Diego , California , Sharon Klahre , Michaela Metzger , Exchange Commission , Twitter , Syndax Pharmaceuticals , European Commission , Syndax Pharmaceuticals Inc , Prnewswire Syndax Pharmaceuticals Nasdaq , Oncology Center , American Society Of Hematology , Pharmaceuticals Inc , Linkedin , Chief Executive , American Society , Meeting Presentations , Orphan Drug Designation , Fast Track , Excellence Review , Rearranged Acute , Mutant Acute Myeloid , Private Securities Litigation Reform Act ,